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Background:  To  specifically  deliver  paclitaxel  (PTX)  to  retinoblastoma  (RB)  cells,  the  anionic  surface-charged
poly(lactic-co-glycolic acid) (PLGA) NPs loaded with paclitaxel were conjugated with epithelial cell adhesion molecule
(EpCAM) antibody for enhancing site-specific intracellular delivery of paclitaxel against EpCAM overexpressing RB
cells.
Methods: PTX-loaded PLGA NPs were prepared by the oil-in-water single emulsion solvent evaporation method, and
the PTX content in NPs was estimated by the reverse phase isocratic mode of high performance liquid chromatography.
Ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride/N-hydroxysuccinimide chemistry was employed for the
covalent  attachment  of  monoclonal  EpCAM  antibody  onto  the  NP  surface.  In  vitro  cytotoxicity  of  native  PTX,
unconjugated PTX-loaded NPs (PTX-NPs), and EpCAM antibody-conjugated PTX-loaded nanoparticles (PTX-NP-
EpCAM) were evaluated on a Y79 RB cell line by a dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, while
cellular  apoptosis,  cysteinyl-aspartic  acid  protease  (caspase)-3  activation,  Poly  (adenosine  diphosphate-ribose)
polymerase (PARP) cleavage, and cell-cycle arrest were quantified by flow cytometry. By employing flow cytometry and
fluorescence image analyses, the extent of cellular uptake was comparatively evaluated.
Results: PTX-NP-EpCAM had superior antiproliferation activity, increased arrested cell population at the G2-M phase,
and increased activation of caspase-3, followed by PARP cleavage in parallel with the induction of apoptosis. Increased
uptake of PTX-Np-EpCAM by the cells suggests that they were mainly taken up through EpCAM mediated endocytosis.
Conclusions: EpCAM antibody-functionalized biodegradable NPs for tumor-selective drug delivery and overcoming
drug resistance could be an efficient therapeutic strategy for retinoblastoma treatment.
Advances  in  our  knowledge  of  molecular  biology  of
cancer and pathways involved in malignant transformation of
cells are revolutionizing the approach to cancer treatment with
a focus on targeted cancer therapy. The newer approaches to
cancer  treatment  not  only  supplement  conventional
chemotherapy  and  radiotherapy  but  also  aim  to  prevent
damage to normal tissues and overcome drug resistance [1].
Nanoparticulate drug delivery systems using biodegradable
polymeric carriers have attracted increasing attention in recent
years. The major advantage of using these nanoparticles (NPs)
is  their  sustained  release  property,  and  since  the  drug  is
encapsulated, it is unexposed to the cell membrane-associated
efflux transporters [2-4]. In this way the efflux action of these
transporters could be bypassed, resulting in greater cellular
drug uptake than that with drug in solution. Polymeric NPs,
primarily  based  on  biodegradable  poly  (D,L-lactic-co-
glycolic  acid;  PLGA)  polymers,  have  been  used  for  the
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administration of water insoluble anticancer agents, such as
paclitaxel  (PTX)  [3,5-8].  Since  PLGA  NPs  cannot  be
delivered to specific cells in a target-specific manner, using
cell  recognizable  targeting  ligands,  such  as  monoclonal
antibodies,  endogenous  targeting  peptides,  and  low-
molecular-weight compounds, such as folate, onto the surface
of the NPs will enhance the intracellular delivery capacity of
polymeric NPs to specific cells [9-13]. One possible approach
of target-specific delivery could be using antibodies directed
toward membrane protein overexpressed by cancer cells.
Earlier we showed that epithelial cell adhesion molecule
(EpCAM), a transmembrane protein, is highly expressed in
retinoblastoma (RB) primary tumors [14], and recently we
demonstrated that EpCAM inhibition leads to decreased RB
cell proliferation in vitro [15]. EpCAM is a 40,000 molecular
weight, type I, transmembrane glycoprotein that consists of
two  epidermal  growth  factor-like  extracellular  domains,  a
cysteine-poor region, a transmembrane domain, and a short
cytoplasmic  tail.  EpCAM  is  overexpressed  in  various
epithelial  cancers  [16]  and  is  an  ideal  therapeutic  target
because of the following reasons: (a) overexpression in cancer
cells  versus  noncancerous  cells,  (b)  apical  expression  in
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2724cancer cells and basolateral expression in normal epithelial
cells [17], and (c) not shed into the circulation [18].
In  this  context,  we  made  use  of  EpCAM  membrane
protein  for  targeted  delivery  of  the  chemotherapy  drug
paclitaxel to retinoblastoma cells that express high EpCAM.
We  formulated  paclitaxel-loaded  PLGA  NP  surfaces
functionalized with EpCAM monoclonal antibody and tested
their efficacy in the retinoblastoma Y79 cell line in vitro.
METHODS
Preparation  of  PTX-loaded  nanoparticles:  PTX-loaded
PLGA  NPs  were  prepared  by  the  oil-in-water,  single
emulsion,  solvent  evaporation  method  with  little
modifications.  In  this  method,  PTX  (equivalent  to  10%
weight/weight [w/w] dry weight of polymer) was dissolved in
3  ml  organic  solvent  (chloroform)  containing  100  mg  of
polymer (PLGA) to form a primary emulsion. The emulsion
was further emulsified in an aqueous poly vinyl alcohol (PVA)
solution (12 ml, 2% w/volume [v]) to form an oil-in-water
emulsion. The emulsification was performed using a microtip
probe sonicator (VC 505; Vibracell Sonics, Newtown, CT) set
at 55 W of energy output for 2 min over an ice bath. The
emulsion was stirred overnight on a magnetic stir plate at room
temperature  to  evaporate  the  organic  solvent.  The  excess
amount  of  PVA  was  removed  the  next  day  by
ultracentrifugation at 8,500 ×g, 4 °C for 20 min (Kendro/
Sorvall  Ultraspeed  Centrifuge,  Artisan  Scientific
Corporation, Champaign, IL), followed by three washes with
double  distilled  water.  The  recovered  nanoparticulate
suspension was lyophilized for 2 days (−80 °C and <10 mm
Hg; LYPHLOCK; Labconco, Kansas City, MO) to obtain
lyophilized powder for further use.
Particle size analysis and zeta potential measurement: To
determine the particle size and zeta potential, 1 mg/ml of NP
solution was prepared in double distilled water. The sample
(100 μl) was diluted to 1 ml, sonicated in an ice bath for 30 s,
and subjected to particle size and zeta potential measurement
using  a  zetasizer  (Zetasizer  nano-zs  ZEN3600;  Malvern
Instrument, Worcestershire, UK).
Transmission electron microscopic studies: NPs were also
evaluated for size by transmission electron microscopy (TEM;
Philips/FEI Inc., Barcliff Manor, NY). For this purpose, a
sample  of  NPs  (0.5  mg/ml)  was  suspended  in  water  and
sonicated for 30 s. One drop of this suspension was placed
over  a  carbon-coated  copper  TEM  grid  (150  mesh;  Ted
PELLA Inc., Redding, CA) and negatively stained with 1%
uranyl acetate for 10 min and then allowed to dry. Images were
visualized at 120 kV under a TEM (Philips/FEI Inc., Barcliff
Manor, NY).
Scanning  electron  microscopic  studies:  The  surface
morphology of NPs was characterized by scanning electron
microscopy  (SEM;  JEOL  JSM-T220A;  Tokyo,  Japan)
operating at an accelerating voltage of 10–30 kV. The NPs
were sputtered with gold to make them conductive and placed
on a copper stub before the acquisition of SEM images.
Estimation  of  entrapment  efficiency  of  Paclitaxel  loaded
nanoparticles: The PTX content in NPs was estimated by the
reverse  phase  isocratic  mode  of  high  performance  liquid
chromatography (HPLC) with slight modification, using an
Agilent  1100  HPLC  (Agilent  Technologies,  Boblingen,
Germany), which consists of a Zorbax Eclipse XDB-C18,
150×4.6 mm internal diameter, with an internal standard of
dimethylphthalate. Briefly, 1 mg of lyophilized PTX-loaded
NPs was dissolved in 1 ml of acetonitrile and kept in a shaker
at 37 °C and 150 rpm (Wadegati Labequip, Mumbai, India)
for 48 h for proper dissolution of the particulate system and
better release of the entrapped drug. After 48 h, samples were
removed from the shaker and centrifuged at 1,000× g for 10
min  at  25  °C  (SIGMA  3K30;  Life-Sciences,  Bremen,
Germany) to extract the drug present in the solution. Five
hundred  microliters  of  the  supernatant  was  collected,  and
20 µl of this supernatant was injected manually in the injection
port and was analyzed using a mobile phase of methanol–
acetonitrile–water (60:5:35; v/v/v). Separation was achieved
by isocratic solvent elution at a flow rate of 1 ml/min with a
quaternary pump (Model No-G1311A, Agilent Technologies)
at  10  °C  with  a  thermostat  (Model  No-G1316A,  Agilent
Technologies). The PTX level was quantified by ultraviolet
Figure  1.  Schematic  presentation  of
epithelial  cell  adhesion  molecule
conjugated  to  paclitaxel-loaded
nanoparticles. The free carboxyl groups
of poly(lactic-co-glycolic acid) (PLGA)
are  covalently  conjugated  to  amine
groups  of  antibody  through
ethyl(dimethylaminopropyl)
carbodiimide  (EDC)/N-
Hydroxysuccinimide (NHS) chemistry.
Abbreviations:  COOH  represents
carboxylic  functional  group;  NH2
represents amine functional group; CO
NH represents amide functional group.
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2725detection at 228 nm (with Diode Array Det [DAD], Model-G
1315A, Agilent Technologies). The amount of PTX in the NPs
was  determined  from  the  peak  area  correlated  with  the
standard curve. The standard curve of PTX was prepared
under identical conditions. All analyses were performed in
triplicate. Triplicate samples were analyzed, and the PTX
encapsulation  efficiency  was  calculated  by  dividing  the
amount of PTX entrapped by the total amount of PTX added,
multiplied by 100.
In vitro release of paclitaxel from nanoparticles: In vitro
release kinetics of PTX from NPs was determined in PBS
buffer  (137  mM  NaCl,  2.7  mM  KCl,  4.3  mM  Na2HPO4,
1.47  mM  KH2PO4;  pH  adjusted  to  7.4  containing  0.1%
Tween-80) at 37 °C. Ten milligrams of NPs was dispersed in
3 ml of the PBS buffer. The NP suspension was equally
divided (1 ml each) in three tubes. These tubes were kept on
a shaker at 37 °C and 150 rpm (Wadegati Labequip, Mumbai,
India). At particular time intervals these tubes were taken from
the shaker and centrifuged at 1,000 ×g, 4 °C for 10 min (Sigma
1–15K microfuge, Shropshire, UK). The supernatants were
removed  to  estimate  the  amount  of  drug  released  at  that
particular time, using reverse phase (RP)-HPLC. The same
amount of fresh PBS was added to the residue, which was
placed back on the shaker for further in vitro release studies
at different time points.
Conjugation of epithelial cell adhesion molecule antibody on
the  surface  of  nanoparticles:  For  covalent  attachment  of
monoclonal EpCAM antibody onto the NP surface, EDC/
NHS chemistry was employed. Briefly, 10 mg of PTX-loaded
NPs was dissolved in 5 ml of PBS (137 mM NaCl, 2.7 mM
KCl, 4.3 mM Na2HPO4, 1.47 mM KH2PO4; pH adjusted to
7.4),  followed  by  drop-wise  addition  of  250  µl  of  EDC
solution (1 mg/ml) and 250 µl of NHS solution (1 mg/ml) in
0.02 M PBS to the NP suspension. The sample was left at room
temperature under agitation for 4 h on a magnetic stirrer. The
sample was then ultracentrifuged at 8,500× g at 4 °C for 20
min  (Sorvall  Ultraspeed  Centrifuge;  Kendro)  to  remove
unreacted EDC and NHS. The process was repeated three
times, and the sediment was washed each time with 1 ml PBS
(0.02 M, pH 7.4). Finally, to dissolve the pellet obtained after
centrifugation, 2 ml of PBS (0.02 M, pH 7.4) was added. We
used  EpCAM-fluorescein  isothiocyanate  (FITC)  for
conjugation to identify the amount of EpCAM conjugated to
NPs. For coupling EpCAM-FITC, the EDC-activated NPs
were  suspended  in  2  ml  of  PBS  (0.02M)  and  500  µl  of
EpCAM-FITC  antibody  (200  µg/ml  in  PBS,  Santa  Cruz
Biotechnology, Santa Cruz, CA) was added drop wise and
stirred for another 2 h at room temperature; this solution was
incubated  overnight  at  4  °C.  The  next  day  unconjugated
EpCAM-FITC was removed by ultracentrifugation and the
supernatant  was  collected  to  calculate  the  conjugation
efficiency.  EpCAM-conjugated  NP  suspension  was
lyophilized to obtain the powder for further use. The collected
supernatant was used to estimate the amount of EpCAM-FITC
that  was  not  conjugated  to  PTX-loaded  NPs,  using  a
fluorescence  spectrophotometer  (Synergy  HT;  BioTek®
Instruments  Inc.,  Winooski,  VT),  and  the  pellet  was
lyophilized  for  further  studies.  The  above  procedure  was
followed to conjugate EpCAM to NPs (EpCAM was used
instead of EpCAM-FITC) for further experiments.
Figure  2.  This  figure  shows  the  size
distribution  of  the  paclitaxel  loaded
poly(lactic-co-glycolic  acid)  (PLGA).
Nanoparticles in terms of the diameter
in nanometers (272±1.6) as estimated by
photon correlation spectroscopy.
Figure  3.  This  figure  shows  the
measurement of zeta potential (surface
charge) of paclitaxel loaded poly(lactic-
co-glycolic acid) (PLGA) nanoparticles
measured  by  photon  correlation
spectroscopy.
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2726Cell lines and cell culture: The Y79 cell line (endogenously
EpCAM-expressing cell line) was obtained from the cell bank,
RIKEN BioResource Center (Ibaraki, Japan). Rosewell Park
Memorial  Institute  (RPMI)  1640  media  and  fetal  bovine
serum (FBS) were purchased from Gibco-BRL (Rockville,
MD). Y79 was cultured in RPMI 1640 medium supplemented
with  10%  heat-inactivated  fetal  calf  serum,  0.1%
ciprofloxacin, 2 mM L-glutamine, 1 mM sodium pyruvate,
and 4.5% dextrose and grown in suspension at 37 °C in a 5%
CO2-humidified  incubator.  The  study  adhered  to  the
Declaration  of  Helsinki.  This  study  was  conducted  at  the
Medical  Research  Foundation  and  Vision  Research
Foundation, Sankara Nethralaya, India, and was approved by
the Vision Research Foundation ethics board.
Y79  cells  treatment  with  native  Free  Paclitaxel  (PTX)/
Paclitaxel loaded Nanoparticles (PTX-NPs)/Epithelial cell
adhesion  molecule  conjugated,  paclitaxel  loaded
Nanoparticles (PTX-NP-EpCAM): Y79 cells (1×105 cells/ml)
were  seeded  on  tissue  culture  treated  flat-bottomed  cell
culture plates (Axygen, Inc. Union city, CA) containing RPMI
media and allowed to grow overnight. The next day, 0.5 µg/
ml  media  containing  native  PTX  and  an  equivalent
concentration  of  freeze-dried  PTX-NPs/PTX-NPs-EpCAM
was added to the wells and the plates were incubated for 48 h
in a CO2 incubator (Hera Cell; Thermo Scientific, Waltham,
MA). Void nanoparticle served as the control. After respective
incubation periods, the cells were washed twice with PBS
(137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.47 mM
KH2PO4; pH adjusted to 7.4) and collected for mitogenic
assay, apoptosis assay, cell-cycle analysis, cysteine-aspartic
proteases  (caspase)-3,  and  poly  (ADP-ribose)  polymerase
(PARP) activity assay
Mitogenic assay: In a dose–response study, cell viability was
determined after 5 days following treatment. A standard (3-
TABLE 1. PHYSICO-CHEMICAL CHARACTERISTICS OF NANOPARTICLE FORMULATIONS.
Formulation Sizea Zeta potentialb PDIc Encapsulation efficiencyd
PTX-NPs 272±1.6 −14.8±2.2 0.17 83
PTX-NP-EpCAM 313±3.3 −13.1±2.5 0.15 79
        aSize in nm as measured by photon correlation spectroscopy. bZetapotential in mV measured by zetasizer. cPolydispersity index
     measured by photon correlation spectroscopy. dPercentage of encapsulation efficiency of NPs measured by RP-HPLC.
Figure 4. Characterization of paclitaxel
loaded  nanoparticles  by  transmission
electron microscopy (TEM). TEM was
used  to  analyze  the  size  and  size
distribution  of  the  paclitaxel  loaded
nanoparticles.
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2727(4, 5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT)-based colorimetric assay was used to determine cell
viability. Reagents were mixed and added to each well (10 µl/
well), plates were incubated for 3 h at 37 °C in a cell culture
incubator, and the color intensity was measured at 490 nm
using  a  microplate  reader  (BioTek,  Winooski,  VT).  The
antiproliferative effect of different treatments was calculated
as a percentage of cell growth with respect to the respective
control.
Assessment of apoptosis by flow cytometry: The induction of
apoptosis by PTX/PTX-NPs/PTX-NP-EpCAM was studied
by  flow  cytometry,  using  the  annexin  FITC  apoptosis
detection kit (BD Biosciences, Mississauga, ON, Canada).
For  apoptosis  study  the  cells  were  pelleted  and  then
resuspended  in  100  µl  of  1×  binding  buffer  (Clontech
Laboratories, Inc., Palo Alto, CA). Thereafter, 5 µl annexin
V-FITC (final concentration, 1 µg/ml; BD Biosciences) and
5 µl propidium iodide (10 µg/µl; MP Biomedicals Inc.) were
added to the cells and incubated at room temperature in the
dark for 20 min. Before flow cytometric analysis 400 µl of 1×
binding  buffer  was  added  to  the  cells  and  the  extent  of
apoptosis was determined by analyzing 15,000 ungated cells,
using a FACScan flow cytometer and Cell Quest software
(FACS  Calibur;  Becton-Dickinson,  San  Jose,  CA).  All
experiments were performed in triplicate.
Cell-cycle analysis: Cell-cycle analysis was studied by flow
cytometry using the BD cycle test plus DNA Reagent kit (BD
Biosciences)  according  to  the  manufacturer’s  protocol.  In
brief, the treated cells were centrifuged, cells were centrifuged
for 5 min at 300× g at room temperature and 1 ml buffer
(DMSO  [DMSO]  in  sucrose-sodium  citrate)  solution  was
added to the supernatant. Cells were resuspended by gentle
vortexing at low speed (procedure repeated twice). Solution
A 206 (250 μl) was added to the cells re-suspended in buffer
solution, and the solution was mixed by tapping and then
incubated for 10 min. Next, 200 μl of solution B was added
and mixed by tapping, followed by incubation for 10 min.
Then, 200 µl of cold solution C (propidium iodide [PI]) was
added to each tube, mixed by tapping, and then incubated for
10 min in the dark on ice. The sample was filtered through a
35-µm cell strainer and analyzed by flow cytometry.
Measurement  of  intracellular  uptake:  One  day  before
treatment, Y79 cells were plated in a 24-well format with
1×105 cells/well containing 1 ml of RPMI 1650 medium with
10% FBS. On the day of treatment, Y79 cells were incubated
with coumarin-labeled NPs (NPs or NP-EpCAM) for 2 days.
Untreated cells were kept as a control. Following incubation,
the cells were harvested, washed twice with PBS, centrifuged
for  5  min  at  500×  g,  and  resuspended  in  ice-cold  PBS.
Intracellular uptake was determined by flow cytometry [19].
Figure 5. Characterization of paclitaxel
loaded  nanoparticles  by  scanning
electron microscopy (SEM). SEM was
used  for  imaging  and  to  study  the
surface  morphology  of  the  paclitaxel
loaded nanoparticles.
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2728Microscopic studies: To study the intracellular retention of
the  drug,  cells  were  treated  with  either  dye,  coumarin  in
solution, or freeze-dried dye-loaded NPs (unconjugated or
conjugated  with  EpCAM  antibody;  10  μg/ml  media).
Untreated cells were used as a control to account for the
autofluorescence, if any. The medium was changed on day 2
after treatment and then every alternate day, and no further
dose of the dye was added. At different time points, the cells
were washed thrice with PBS to remove any uninternalized
dye and then visualized using an Axio Observer fluorescent
microscope (Carl Zeiss, Berlin, Germany) equipped with an
argon laser with an excitation wavelength set at 488 nm and
emission at 525 nm [20]. Detection was with a band-pass
emission barrier filter. The images were processed using Axio
Vision 4.7 software (Carl Zeiss, Bangalore, India).
Caspase-3  and  poly  (Adenosine  Diphosphate-ribose)
polymerase activity assay by flow cytometer: For intracellular
staining,  cells  were  fixed  and  permeabilized  with  2%
paraformaldehyde and 0.05% Tween-20 to allow intracellular
labeling  with  the  respective  cleaved  PARP  antibody
(ab32064; Abcam, San Francisco, CA), and cleaved caspase-3
antibody (Cell Signaling, Danvers, MA; 1:200 dilution) was
added and incubated for 1 h. Following incubation, cells were
washed  twice  with  ice-cold  PBS  and  incubated  with
secondary FITC-antirabbit immunoglobulin (Sigma, 1:1,000
dilution) for 30 min at 4 °C. Cells were then washed twice
with ice-cold PBS, resuspended in FACS buffer, and analyzed
by FACS.
Statistical analysis: All experiments were repeated at least
three  times.  ANOVA  (ANOVA)  was  used  for  statistical
analysis. The differences were considered significant for p
values of <0.05.
RESULTS
Characterization  of  paclitaxel-loaded  nanoparticles
conjugated with epithelial cell adhesion molecule antibody:
PTX-loaded  NPs  were  prepared  by  the  single  emulsion
method  as  described  in  the  methodology.  EpCAM  was
covalently conjugated to the carboxylic group of PLGA NPs
by  the  EDC  and  NHS  activation  method  (Figure  1).  The
amount  of  EpCAM-FITC  antibody  conjugated  to  the
nanoparticle  surface  was  determined  by  fluorescence
spectrophotometry.  Approximately  7.8  µg  of  EpCAM
antibody  was  found  to  attach  per  milligram  of  the
nanoparticle. Dynamic light scattering analysis revealed that
the  formulated  nanoparticle  had  an  average  diameter  of
272±1.6  nm  (Figure  2)  with  a  negative  zeta  potential  of
-14.8±2.2 mV (Figure 3). On measuring the size of EpCAM-
conjugated NPs, a negligible increase in the size of NPs (272
to 313 nm) was observed after conjugation of EpCAM to the
NP surface (Table 1). The zeta potential of NP-EpCAM was
comparatively less than unconjugated NPs (-14.8±2.2 mV
versus  -13.1±2.5  mV;  Table  1).  TEM  images  showed  a
Figure  6.  The  line  graph  shows  the
cumulative  percentage  release  of
paclitaxel drug into the phosphate buffer
solution  (PBS)  buffer  from  the
paclitaxel loaded nanoparticles over a
period  of  time  (in  days).  Error  bars
represents  that  experiments  were
performed in triplicates.
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2729discrete spherical outline and monodispersed size distribution
(~100 nm) of PLGA NPs (Figure 4). The topology of the NPs
as  observed  by  SEM  analysis  confirmed  the  smooth  and
spherical nature of PTX-NPs (Figure 5). The encapsulation
efficiency of the NPs was around 83% (i.e., 83% of the drug
added in formulation was entrapped in NPs) as estimated by
RP-HPLC.  After  conjugation  the  encapsulation  efficiency
slightly decreased to about 79%.
In vitro release of paclitaxel by nanoparticles: In the in vitro
release study, NPs demonstrated a sustained release of the
encapsulated drug, with approximately 38% cumulative drug
release in 21 days (Figure 6). The NPs gave a comparatively
faster release (~22% in 1 day) followed by a slow release
(~38% in 21 days) of the drug from the polymeric matrix.
Cytotoxicity assay: The ability of the PTX-NPs (conjugated
or unconjugated) to deliver PTX and induce cell death was
examined on the retinoblastoma cell line (Y79) by the MTT
assay. Results demonstrated that cell viability of the Y79 cell
line was affected by different concentrations of PTX as well
as  PTX-NPs/PTX-NP-EpCAM.  Greater  antiproliferative
activity  was  observed  for  almost  all  doses  of  PTX-NP-
EpCAM compared to that of the native PTX and PTX-NP
(Figure 7A). PTX-NP-EpCAM-treated Y79 cells exhibited an
inhibitory concentration 50 (IC50) value as low as 0.005 µg/
ml, while native PTX and PTX-NP had an IC50 value as high
as  0.05  and  3.5  µg/ml,  respectively.  Another  important
observation was the increase in the antiproliferative activity
of the drug with incubation time (day 5) when cells were
treated with low doses of the drug using PTX-NP-EpCAM
(PTX dose=0.005 µg/ml; Figure 7B). Differences between the
native PTX and PTX-NPs (conjugated or unconjugated) were
significantly evident after 5 days of drug treatment as they
showed  significantly  greater  antiproliferative  effect  (42%
inhibition  by  PTX-NP-EpCAM  versus  71%  and  60%
inhibition by native PTX and PTX-NP, respectively). The
Y79  cells  were  treated  with  native  PTX  and  PTX-NP
(conjugated and unconjugated) for 2 days in vitro. The cells
were harvested on day 2 for an apoptotic assay using FACS.
Following  treatment  with  native  PTX,  Y79  cells  showed
2.91% apoptosis (1.68% of early apoptosis, 1.23% of late
apoptosis), and with PTX-NP, Y79 cells showed 8.06% of
apoptosis (6.93% early apoptosis and 1.13% late apoptosis).
In contrast, Y79 cells treated with PTX-NP-EpCAM showed
increased late apoptosis (17.16% early apoptosis; 2.24% late
apoptosis; Figure 8).
Figure  7.  Dose  and  time-dependent
cytotoxicity  of  paclitaxel  (PTX)  and
PTX loaded nanoparticles (NPs) in Y79
cells. A and B: Different concentrations
of  PTX  either  as  solution  or  PTX
encapsulated in NPs or Epithelial cell
adhesion molecule antibody-conjugated
PTX-NPs were added to the wells with
medium.  The  extent  of  growth
inhibition was measured at 48 h and at
day 5 by the (3-(4, 5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium  bromide
(MTT) assay. Inhibition was calculated
with  respect  to  respective  controls.
Experiments  were  performed  in
triplicates and the data are represented
as mean±standard error (*p<0.001).
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2730Increased  caspase-3  activation  and  Poly  (adenosine
diphosphate-ribose) polymerase cleavage in Y79 cells treated
with epithelial cell adhesion molecule antibody conjugated
paclitaxel loaded nanoparticles: To determine whether the
apoptosis of Y79 cells induced by PTX is a specific caspase-
dependent pathway, we analyzed the effect of native PTX,
PTX-NPs,  and  PTX-NP-EpCAM  on  caspase-dependent
apoptosis. Caspase activation followed by cleavage of PARP
was enhanced in Y79 cells treated with PTX-NP-EpCAM
compared to PTX-NP and native PTX. Active caspase-3 was
positive in 23.76% cells, and 16.93% cells were positive for
cleaved  PARP  after  treatment  with  PTX-NP-EpCAM;
13.22% cells were positive for active caspase-3 and 7.11%
cells for cleaved PARP with PTX-NPs; 9.28% of cells were
positive  for  active  caspase-3  and  4.66%  cells  for  cleaved
PARP with native PTX (Figure 9 and Figure 10).
Enhanced G2-M phase halt in Y79 cells treated with epithelial
cell adhesion molecule antibody conjugated paclitaxel loaded
Figure 8. Apoptotic effects of paclitaxel
loaded nano-conjugates on Y79 cells.
Flow  cytometry  analysis  showing  the
effect of control (A), native paclitaxel
(PTX;  B),  PTX-loaded  nanoparticles
(PTX-NP; C), and PTX-NP conjugated
with epithelial cell adhesion molecule
antibody  (PTX-NP-EpCAM;  D)
treatment  on  Y79  cells  after  48  h
incubation. The Y79 cells treated with
PTX-NP-EpCAM showed significantly
higher (p<0.001) early and intermediary
apoptotic events compared to PTX-NP
or  native  PTX.  Abbreviation:  PI
represents propidium iodide.
Figure  9.  Analysis  of  caspase-3
expression  in  paclitaxel  loaded  nano-
conjugates.  Flow  cytometry  analysis
showing caspase-3 expression in Y79
cells  after  the  treatment  with  control
(A); native paclitaxel (PTX; B); PTX-
loaded nanoparticles (PTX-NP; C), and
PTX-NP conjugated with epithelial cell
adhesion molecule antibody (PTX-NP-
EpCAM;  D).  Increased  caspase
expression  was  noted  in  Y79  cells
treated  with  PTX-NP-EpCAM
compared to PTX-NP or native PTX.
Molecular Vision 2011; 17:2724-2737 <http://www.molvis.org/molvis/v17/a295> © 2011 Molecular Vision
2731nanoparticles:  We  quantified  the  percentage  of  cells  at
various phases of the cell cycle and plotted them against the
native  PTX/PTX-NP/PTX-NP-EpCAM  (Figure  11).  In
untreated Y79, 3.84% cells were at the G2-M phase. When
exposed to native PTX and PTX-NP, the arrested population
increased about 12.2% and 17.8%, and the increase continued
progressively to 21.7% with PTX-NP-EpCAM.
Increased  uptake  of  coumarin-6  labeled  epithelial  cell
adhesion molecule antibody conjugated nanoparticles by Y79
cells: To explain the increased cytotoxicity of the PTX-NP-
EpCAM formulation, the intracellular uptake of NP-EpCAM
was quantitatively examined in an EpCAM-overexpressing
Y79  cell  line  (Figure  12).  In  the  case  of  NP-EpCAM,
increased fluorescence intensity profiles to the right direction
indicates that the cellular uptake was significantly enhanced
due to EpCAM-mediated endocytosis.
The extent of cellular uptake for NP-EpCAM was about
twofold greater than that of EpCAM antibody unconjugated
NPs and tenfold greater than the free coumarin-6 dye, (Figure
12). The fluorescence intensity was twofold less in the HeLa
cell line, which does not express EpCAM compared to uptake
in Y79 cells. This clearly shows that EpCAM on Y79 cells
mediates the specific uptake of NP-EpCAM.
Prolonged retention of NP-EpCAM in Y79 cells: To further
confirm the enhanced intracellular uptake of NP-EpCAM,
fluorescence microscopic analysis was performed. Y79 cells
incubated with free coumarin in solution demonstrated drug
internalization within 4 h of incubation, but with increase in
incubation time, the fluorescent intensity decreased slowly.
EpCAM-conjugated coumarin-loaded NPs on the other hand
were more strongly stained with clear visualization of the
internalized TXNPs, and in addition they showed a significant
increase in fluorescence intensity with incubation time, with
strong  fluorescence  even  after  5  days  of  treatment  as
compared to the unconjugated coumarin-loaded NPs and free
coumarin (Figure 13). In this study we envisioned that the
uptake  of  EpCAM-conjugated  NPs  via  EpCAM-mediated
endocytosis could have an intracellular disposition pathway
different from that of unconjugated NPs. This could influence
the intracellular retention of NPs and hence the therapeutic
efficacy of the encapsulated drug in retinoblastoma. Our study
shows  that  the  EpCAM-conjugated  PLGA  NPs  could  be
potentially applied to target-specific intracellular delivery of
various hydrophobic anticancer agents.
DISCUSSION
Functionalization of NPs with tumor-targeting ligands, such
as  antibodies  or  peptides,  directed  against  overexpressed
tumor markers not only enhances localization of the particles
to the solid tumor mass but also allows the NPs to target early
stage  tumors  and  metastatic  tumor  cells.  Treatment  with
monoclonal antibody (mAbs) is a viable therapeutic option in
cancer.  Recently,  these  mAbs,  such  as  cetuximab  and
herceptin, have been used as targeting agents to selectively
deliver  chemotherapeutics  to  cancerous  cells  [21].  For
example, Reddy et al. has used folic acid-coated polymeric
NPs  and  demonstrated  enhanced  localization  and
internalization of NPs for drug delivery to breast cancer cells
[22], whereas Zhang et al. has shown that folic acid-coated
magnetite  NPs  demonstrated  improved  localization  and
internalization intended for tumor imaging of breast cancer
cells [23]. Similarly, tagging anti-HER2 to the nanoparticle
surface  greatly  improved  cell  internalization  of  gelatin/
albumin [24]
Our objective in the present study was to examine the
target-specific intracellular delivery capacity of PLGA NPs
by coating EpCAM antibody on their surface. Although the
prepared  PLGA  NPs  with  a  nanoscale  size  distribution
accumulated at the solid tumor site in a passive targeting
manner by an “enhanced permeation and retention” effect
[22],  cell-specific  targeting  ability  by  EpCAM  antibody
Figure 10. Analysis of Poly (adenosine
diphosphate-ribose)  polymerase
expression  in  paclitaxel  loaded  nano-
conjugates.  Flow  cytometry  analysis
showing PARP activation in Y79 cells
after  the  treatment  with  control  (A);
native paclitaxel (PTX; B); PTX-loaded
nanoparticles (PTX-NP; C), and PTX-
NP  conjugated  with  epithelial  cell
adhesion molecule antibody (PTX-NP-
EpCAM;  D).  Increased  PARP
activation was noted in Y79 cells treated
with  PTX-NP-EpCAM  compared  to
PTX-NP or native PTX.
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2732Figure 11. Cell cycle analysis of Y79 cells treated with paclitaxel loaded nano-conjugates. Increased G2-M arrest was observed by flow
cytometry analysis in Y79 cells treated with paclitaxel-loaded nanoparticles conjugated with epithelial cell adhesion molecule antibody (PTX-
NP-EpCAM) at 48 h compared to paclitaxel-loaded nanoparticles (PTX-NP) or native paclitaxel (PTX). A: Untreated Y79 cells showing 3.8%
of G2-M phase after doublet discrimination. B: Y79 cells treated with native paclitaxel showing increased G2-M cells (12.2%). C: Y79 cells
treated with PTX-NP showing 17.8% of G2-M phase. D: Y79 cells treated with PTX-NP-EpCAM showing 21.7% G2-M phase.
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2733conjugation is responsible for promoting their intracellular
uptake within EpCAM-expressing cancer cells. PTX-loaded
NPs  were  prepared  by  the  single  emulsion  method,  and
EpCAM  moieties  were  covalently  conjugated  to  the
carboxylic  group  of  PLGA  NPs  by  the  EDC  and  NHS
activation method for cell recognition. The enhancement of
cellular uptake was gained via an EpCAM receptor-mediated
intracellular delivery mechanism.
Fluorescent  microscopy  and  flow  cytometry  analysis
revealed  increased  uptake  of  NP-EpCAM  by  Y79  cells
compared to unconjugated NPs or native coumarin-6 dye.
Interestingly, PTX-NP-EpCAM showed an increase in the
antiproliferative  activity  of  the  drug  with  incubation  time
when cells were treated with low doses of the drug using PTX-
NP-EpCAM  (PTX  dose=0.005  µg/ml).  PTX-NP-EpCAM
showed higher apoptotic events in Y79 cells as evidenced by
caspase-3 activation. The induction of apoptosis is considered
to be one of the principle mechanisms by which PTX induces
tumor regression in retinoblastoma [23,24]. Suarez et al. [23]
has  shown  that  paclitaxel  administered  through  the
subconjunctival route effectively inhibited the retinoblastoma
tumor burden in the LH beta-Tag animal models. However,
higher doses of native drug administration are associated with
ocular  tissue  toxicities  [23].  For  improved  sustain  drug
release, PLGA NPs were used to deliver drugs in diabetic rat
models  through  subconjunctival  administration  [25].  This
approach reduces the ocular tissue toxicity associated with
native drugs and enhances sustained drug release for effective
therapeutic response. Our present study has further modified
the paclitaxel-containing PLGA NPs with EpCAM antibody
for targeted and sustained drug release to RB cells.
One  of  the  key  initiation  elements  of  the  apoptotic
pathway is the activation of caspases followed by cleavage of
the caspase substrates [26]. The 113-kDa PARP-1, which is
normally involved in DNA repair, DNA stability, and other
cellular events, is cleaved by members of the caspase family
during early apoptosis. PTX-NP-EpCAM showed increased
G2-M phase arrest in Y79 cells compared to PTX-NP or native
PTX. Previous studies have shown that PTX arrests cells at
the G2-M phase of the cell cycle [27,28] and that defects of
spindle assembly or the presence of detached chromosomes
activates an internal signaling pathway that probably initiates
the induction of PTX-induced apoptosis [29].
Figure 12. Flow cytometry analysis of
uptake  of  nanoparticles  by  Y79  cells
Flow  cytometry  analysis  showed
significantly higher uptake of coumarin
encapsulated  nanoparticles  conjugated
with epithelial cell adhesion molecule
antibody  (COU-NP-EpCAM)  by  Y79
cells compared to that of unconjugated
coumarin encapsulated nanoparticles.”
EpCAM negative cell line HeLa cells
were  used  as  negative  control  which
showed  relatively  less  uptake  (mean
intensity  -1144.44)  compared  to
EpCAM  positive  Y79  cells  (mean
intensity -2090.80).
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2734Figure 13. Microscopic analysis of uptake of nanoparticles by Y79 cells. Fluorescent microscopic analysis showing the uptake of native
coumarin (A-D), coumarin encapsulated nanoparticles (COU-NP; E-H), and coumarin encapsulated nanoparticles conjugated with epithelial
cell adhesion molecule antibody (COU-NP-EpCAM; K-N) at 4 h (A, E, K), day 1 (B, F, L), day 2 (C, G, M), and day 5 (D, H, N). The Y79
cells showed increased COU-NP-EpCAM uptake compared to unconjugated COU-NP at all time points. Increased coumarin-NP retention
was observed in the Y79 cells even at day 5 when compared to free coumarin.
Molecular Vision 2011; 17:2724-2737 <http://www.molvis.org/molvis/v17/a295> © 2011 Molecular Vision
2735To  conclude,  this  study  demonstrates  the  proof  of
principle of using EpCAM antibody to specifically deliver the
chemotherapy drugs to retinoblastoma cells. Further in vivo
studies  are  warranted  to  use  this  formulation  in  clinical
settings  for  retinoblastoma  and  other  EpCAM-expressing
cancer management.
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